Sponsor Study ID:
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This is a Phase 2, multi-center, open-label, single-arm study. The study will enroll approximately 140 patients.
A 2-stage design will be used, with an interim analysis for futility on the first 52 patients. If =10 patients respond (CR+PR), the study will proceed to complete full enrollment. Enrollment will continue during the interim analysis; however, further enrollment will be halted if futility is confirmed.
If you would like to contact a MUSC study team member to learn more information about this study, click